Brief: Immix Biopharma To Present Milestones Achieved To Enable Kick-Off Of 2 Imx-110 Clinical Trials At The 2022 Thinkequity Conference On October 26
25/10/2022 15:33
Oct 25 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA TO PRESENT MILESTONES ACHIEVED TO ENABLE
KICK-OFF OF 2 IMX-110 CLINICAL TRIALS AT THE 2022 THINKEQUITY
CONFERENCE ON OCTOBER 26
Source text for Eikon: ID:nGNX5NmgJz
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary